Obesity
-
【Urgent】MNC, China big pharma, US biotech are looking for ActRIIA and ActRIIB Inhibitors for obesity and other indications
If your company is interested in this opportunity, please contact us as soon as possible!
-
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
Structure Therapeutics announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives
